3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Doxorubicin
44
Imatinib Mesylate
33
pembrolizumab
23
Cyclophosphamide
23
Sunitinib
22
Gemcitabine
22
Temozolomide
17
Irinotecan
14
Bevacizumab
14
Docetaxel
13
nilotinib
12
Trabectedin
12
ripretinib
11
pazopanib
11
olaratumab
10
fludarabine
10
eribulin
10
regorafenib
9
avapritinib
9
Fluorouracil
9
Carboplatin
9
Paclitaxel
8
Nivolumab
8
Ifosfamide
8
Ibandronic Acid
8
spartalizumab
7
anlotinib
7
Vincristine
7
Radiation
7
Ipilimumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
tinostamustine
×
Sarcoma
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts